Skip to main content
Contact Us
Subscribe
E-Edition
87°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eliem Therapeutics Inc
(NQ:
ELYM
)
6.000
+0.190 (+3.27%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Eliem Therapeutics Inc
< Previous
1
2
3
4
Next >
Eliem Therapeutics Announces Plans to Explore Strategic Alternatives
July 20, 2023
From
Eliem Therapeutics, Inc.
Via
GlobeNewswire
Eliem Therapeutics Reports First Quarter Financial Results and Business Highlights
May 11, 2023
From
Eliem Therapeutics, Inc.
Via
GlobeNewswire
Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights
March 06, 2023
From
Eliem Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
February 23, 2023
Via
Benzinga
Eliem Pauses Development On Depression Drug, Lays Off 55% Workforce
February 10, 2023
Via
Benzinga
Eliem Therapeutics Outlines Interim Data From Early-Stage Depressive Study
October 05, 2022
Via
Benzinga
Eliem Therapeutics: Q2 Earnings Insights
August 15, 2022
Eliem Therapeutics (NASDAQ:ELYM) reported its Q2 earnings results on Monday, August 15, 2022 at 08:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 20, 2023
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 17, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023
February 10, 2023
Via
Benzinga
Eliem Therapeutics Shares Fall On Lower Back Pain Trial Setback
August 02, 2022
Via
Benzinga
Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition
February 09, 2023
From
Eliem Therapeutics, Inc.
Via
GlobeNewswire
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
January 04, 2023
Gainers Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive...
Via
Benzinga
Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference
November 30, 2022
From
Eliem Therapeutics, Inc.
Via
GlobeNewswire
Eliem Therapeutics Reports Third Quarter Financial and Business Highlights
November 14, 2022
From
Eliem Therapeutics, Inc.
Via
GlobeNewswire
Eliem Therapeutics to Participate at Two Upcoming Investor Conferences
November 08, 2022
From
Eliem Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 28, 2022
October 28, 2022
Upgrades
Via
Benzinga
Eliem Therapeutics Provides Update on Pipeline Progress
October 05, 2022
From
Eliem Therapeutics, Inc.
Via
GlobeNewswire
Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From Yesterday
September 23, 2022
Gainers
Via
Benzinga
SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know
August 16, 2022
SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $9.00 to $4.00. Shares of Eliem Therapeutics are trading down 2.08% over...
Via
Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
August 02, 2022
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
August 02, 2022
Via
Benzinga
Recap of Monday's Biotech Catalysts - End of the Day Summary
July 18, 2022
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least...
Via
Benzinga
Eliem Announces Updated Development Plans For Its Delayed Depression Candidate
July 18, 2022
In April, Eliem Therapeutics Inc (NASDAQ: ELYM) delayed ETX-155 into Phase 2a depression trials to determine the root cause of a lower-than-expected exposure observed in a Phase 1b study in...
Via
Benzinga
This Technology Stock Surged 235%; Here Are 77 Biggest Movers From Friday
July 25, 2022
Gainers
Via
Benzinga
SVB Leerink Maintains Outperform Rating for Eliem Therapeutics: Here's What You Need To Know
July 11, 2022
SVB Leerink has decided to maintain its Outperform rating of Eliem Therapeutics (NASDAQ:ELYM) and lower its price target from $13.00 to $9.00. Shares of Eliem Therapeutics are trading down 4.04% over...
Via
Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
June 28, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Eliem Concludes Patient Enrolment In Mid-Stage Study Of Radicular Back Pain Drug
June 27, 2022
Eliem Therapeutics (NASDAQ: ELYM) has completed dosing of the last patient in its Phase 2a trial of ETX-810 in patients with chronic lumbosacral radicular pain (LSRP).
Via
Benzinga
5 Short Squeeze Candidates To Watch This Week: Revlon Tops The List, A SPAC Shifts To Second And More
June 21, 2022
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
June 16, 2022
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.